Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdCLD-CoV19-1 OMI Booster in Healthy Adults
NCT05576623Phase 2Completed
- Sponsor
- Cellid Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AdCLD-CoV19-1 OMI in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Cellid Co., Ltd. Primary endpoints: Proportion of immediate adverse events at 30 minutes, Proportion of solicited local and systemic AE at 7 days and 6 more. Started Sep 2022; status: completed.
02
Drugs
AdCLD-CoV19-1 OMI
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05576623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576623.